NCT04812002View on ClinicalTrials.gov

Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 15, 2021

Primary Completion Date

April 15, 2024

Study Completion Date

April 15, 2026

Conditions
Gestational Trophoblastic Neoplasia
Interventions
DRUG

PD-1 inhibitor， bevacizumab

Both drugs are given intravenously

Trial Locations (1)

310000

RECRUITING

Women's Hospital School of Medicine Zhejiang University, Hangzhou

All Listed Sponsors
lead

Women's Hospital School Of Medicine Zhejiang University

OTHER